For patients with mild to moderate COVID-19 disease considered to be at high risk of progressing to severe COVID-19 disease monoclonal antibody therapy such as REGEN-COV (casirivimab and imdevimab) may help reduce the severity of COVID-19 illness and aids efforts to prevent COVID-19 illness from worsening and/or resulting in hospitalization for further treatment.  There are currently no approved drugs or other therapeutic agents for the treatment of mild to moderate COVID-19, but casirivimab and imdevimab may present the best available therapy for assisting your body to fight this virus.  

Things to have ready before your appointment:

• Please bring your medical/medicare and prescription insurance card. There is no fee for the patient at the time of the appointment. We will attempt to bill your insurance for the treatment fee, but some insurances will have copays and you may receive a bill in the future. Also, please bring photo ID to your appointment.

• Please review and if possible, print and sign our REGEN-COV Monoclonal antibody consent form prior to your appointment. Click here for the consent form.

• Please review the Fact Sheet/Emergency Use Authorization (EUA) for REGEN-COV (casirivimab and imdevimab) prior to your appointment.